LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 341

Search options

  1. Book: Pluripotent Stem Cell Therapy for Diabetes

    Piemonti, Lorenzo / Odorico, Jon / de Koning, Eelco / Sordi, Valeria / Kieffer, Timothy J

    2024  

    Author's details Lorenzo Piemonti, M.D., is Professor of Endocrinology at the University of Vita-Salute San Raffaele. He specializes in the field of diabetes and pancreatology, with a particular focus on diabetes therapy and pathophysiology, regenerative medicine, and pancreatic cancer. Dr. Piemonti has extensive experience and expertise in beta cell replacement, immune tolerance induction strategies, dendritic cell biology, and stem cells. His research contributions have significantly advanced our understanding of these areas and their implications for diabetes management. Jon S Odorico, M.D., is a distinguished Professor of Surgery in the Section of Kidney and Pancreas Surgery and Division of Transplantation at the University of Wisconsin School of Medicine and Public Health. He is renowned for his expertise in transplantation, including islet transplantation and pancreatology. Dr. Odorico's research and clinical work have made substantial contributions to the field, particularly in the area of pa
    Keywords Regenerative Medicine ; Autoimmunity ; immunoescape ; pluripotent stem cells ; tissue engineering diabetes ; stem cell diabetes ; regenerative medicine diabetes ; autoimmunity diabetes ; pluripotent stem cells diabetes ; Stem cell ; Regenerative medicine ; diabetes ; autoimmunity
    Language English
    Size 620 p.
    Edition 1
    Publisher Springer International Publishing
    Document type Book
    Note PDA Manuell_25
    Format 160 x 241 x 39
    ISBN 9783031419423 ; 3031419421
    Database PDA

    Kategorien

  2. Article ; Online: Felix dies natalis, insulin… ceterum autem censeo "beta is better".

    Piemonti, Lorenzo

    Acta diabetologica

    2021  Volume 58, Issue 10, Page(s) 1287–1306

    Abstract: One hundred years after its discovery, insulin remains the life-saving therapy for many patients with diabetes. It has been a 100-years-old success story thanks to the fact that insulin therapy has continuously integrated the knowledge developed over a ... ...

    Abstract One hundred years after its discovery, insulin remains the life-saving therapy for many patients with diabetes. It has been a 100-years-old success story thanks to the fact that insulin therapy has continuously integrated the knowledge developed over a century. In 1982, insulin becomes the first therapeutic protein to be produced using recombinant DNA technology. The first "mini" insulin pump and the first insulin pen become available in 1983 and 1985, respectively. In 1996, the first generation of insulin analogues were produced. In 1999, the first continuous glucose-monitoring device for reading interstitial glucose was approved by the FDA. In 2010s, the ultra-long action insulins were introduced. An equally exciting story developed in parallel. In 1966. Kelly et al. performed the first clinical pancreas transplant at the University of Minnesota, and now it is a well-established clinical option. First successful islet transplantations in humans were obtained in the late 1980s and 1990s. Their ability to consistently re-establish the endogenous insulin secretion was obtained in 2000s. More recently, the possibility to generate large numbers of functional human β cells from pluripotent stem cells was demonstrated, and the first clinical trial using stem cell-derived insulin producing cell was started in 2014. This year, the discovery of this life-saving hormone turns 100 years. This provides a unique opportunity not only to celebrate this extraordinary success story, but also to reflect on the limits of insulin therapy and renew the commitment of the scientific community to an insulin free world for our patients.
    MeSH term(s) Aged, 80 and over ; Diabetes Mellitus/drug therapy ; Diabetes Mellitus, Type 1/drug therapy ; Humans ; Insulin ; Insulin Infusion Systems ; Islets of Langerhans Transplantation ; Pancreas Transplantation
    Chemical Substances Insulin
    Language English
    Publishing date 2021-05-23
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 1097676-0
    ISSN 1432-5233 ; 0940-5429
    ISSN (online) 1432-5233
    ISSN 0940-5429
    DOI 10.1007/s00592-021-01737-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Comment on Total Pancreatectomy With Islet Autotransplantation as an Alternative to High-Risk Pancreatojejunostomy After Pancreaticoduodenectomy: A Prospective Randomized Trial.

    Balzano, Gianpaolo / Zerbi, Alessandro / Scavini, Marina / Piemonti, Lorenzo

    Annals of surgery open : perspectives of surgical history, education, and clinical approaches

    2023  Volume 4, Issue 1, Page(s) e262

    Language English
    Publishing date 2023-02-22
    Publishing country United States
    Document type Journal Article
    ISSN 2691-3593
    ISSN (online) 2691-3593
    DOI 10.1097/AS9.0000000000000262
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Response to: Comment on: Pancreatectomy With Islet-Autotransplantation as Alternative for Pancreato-Duodenectomy in Patients With a High-Risk for Postoperative Pancreatic Fistula: The Jury Is Still Out.

    Balzano, Gianpaolo / Zerbi, Alessandro / Scavini, Marina / Piemonti, Lorenzo

    Annals of surgery open : perspectives of surgical history, education, and clinical approaches

    2023  Volume 4, Issue 1, Page(s) e261

    Language English
    Publishing date 2023-01-30
    Publishing country United States
    Document type Journal Article
    ISSN 2691-3593
    ISSN (online) 2691-3593
    DOI 10.1097/AS9.0000000000000261
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Enhancing Beta Cell Replacement Therapies: Exploring Calcineurin Inhibitor-Sparing Immunosuppressive Regimens.

    Caldara, Rossana / Tomajer, Valentina / Piemonti, Lorenzo

    Transplant international : official journal of the European Society for Organ Transplantation

    2023  Volume 36, Page(s) 11565

    MeSH term(s) Humans ; Calcineurin Inhibitors/therapeutic use ; Immunosuppressive Agents/therapeutic use ; Mycophenolic Acid ; Graft Rejection/prevention & control
    Chemical Substances Calcineurin Inhibitors ; Immunosuppressive Agents ; Mycophenolic Acid (HU9DX48N0T)
    Language English
    Publishing date 2023-06-08
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 639435-8
    ISSN 1432-2277 ; 0934-0874
    ISSN (online) 1432-2277
    ISSN 0934-0874
    DOI 10.3389/ti.2023.11565
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Reparixin improves survival in critically ill and transplant patients: A meta-analysis.

    Piersanti, Gioia / Landoni, Giovanni / Scquizzato, Tommaso / Zangrillo, Alberto / Piemonti, Lorenzo

    European journal of clinical investigation

    2023  Volume 53, Issue 10, Page(s) e14015

    Abstract: Background: Reparixin, an anti-inflammatory drug that inhibits interleukin 8 (IL-8) activity, might be life-saving for high-risk in-hospital patients without increasing the risk of infection according to a previous meta-analysis. With the increasing ... ...

    Abstract Background: Reparixin, an anti-inflammatory drug that inhibits interleukin 8 (IL-8) activity, might be life-saving for high-risk in-hospital patients without increasing the risk of infection according to a previous meta-analysis. With the increasing availability of randomised data the aim of the current study is to update previous findings by including any randomised control trials (RCTs) investigating the impact of reparixin on survival of critically ill or transplant patients.
    Methods: A search strategy was developed to identify all RCTs involving reparixin in critically ill or transplant patients, with the exclusion of oncological patients. Two trained and independent authors conducted a thorough search of relevant databases. In addition, backward snowballing was employed. Language restrictions were not imposed.
    Results: Our analysis included a total of nine studies involving 733 patients: 437 received reparixin and 296 the comparator. The reparixin group had a significantly lower all-cause mortality rate compared to the control group [15/437 (3.4%) vs. 19/294 (6.4%), odds ratio = 0.47 (95% confidence interval 0.23-0.96), p-value for effect .04, I2 = 22%, number needed to treat = 33]. These findings had the same direction and magnitude of effect across COVID-19 patients (n = 325) and non-COVID-19 patients (n = 408). Furthermore, there were no significant differences in the rate of pneumonia, sepsis or non-serious infections between the two groups.
    Conclusions: The findings of this meta-analysis indicate that reparixin, an anti-inflammatory drug, improved survival in critically ill or transplant patients (including both COVID-19 and non-COVID-19 patients) without increasing the risk of infection.
    MeSH term(s) Humans ; COVID-19 ; Critical Illness
    Chemical Substances reparixin (U604E1NB3K)
    Language English
    Publishing date 2023-05-09
    Publishing country England
    Document type Meta-Analysis ; Journal Article ; Review
    ZDB-ID 186196-7
    ISSN 1365-2362 ; 0014-2972 ; 0960-135X
    ISSN (online) 1365-2362
    ISSN 0014-2972 ; 0960-135X
    DOI 10.1111/eci.14015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Cell Therapy for Type 1 Diabetes: From Islet Transplantation to Stem Cells.

    Sordi, Valeria / Monaco, Laura / Piemonti, Lorenzo

    Hormone research in paediatrics

    2022  Volume 96, Issue 6, Page(s) 658–669

    Abstract: The field of cell therapy of type 1 diabetes is a particularly interesting example in the scenario of regenerative medicine. In fact, β-cell replacement has its roots in the experience of islet transplantation, which began 40 years ago and is currently a ...

    Abstract The field of cell therapy of type 1 diabetes is a particularly interesting example in the scenario of regenerative medicine. In fact, β-cell replacement has its roots in the experience of islet transplantation, which began 40 years ago and is currently a rapidly accelerating field, with several ongoing clinical trials using β cells derived from stem cells. Type 1 diabetes is particularly suitable for cell therapy as it is a disease due to the deficiency of only one cell type, the insulin-producing β cell, and this endocrine cell does not need to be positioned inside the pancreas to perform its function. On the other hand, the presence of a double immunological barrier, the allogeneic one and the autoimmune one, makes the protection of β cells from rejection a major challenge. Until today, islet transplantation has taught us a lot, pioneering immunosuppressive therapies, graft encapsulation, tissue engineering, and test of different implant sites and has stimulated a great variety of studies on β-cell function. This review starts from islet transplantation, presenting its current indications and the latest published trials, to arrive at the prospects of stem cell therapy, presenting the latest innovations in the field.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 1/surgery ; Islets of Langerhans Transplantation ; Stem Cells/metabolism ; Cell- and Tissue-Based Therapy ; Insulin-Secreting Cells/metabolism
    Language English
    Publishing date 2022-08-30
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2537278-6
    ISSN 1663-2826 ; 1663-2818
    ISSN (online) 1663-2826
    ISSN 1663-2818
    DOI 10.1159/000526618
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Prevalence of undiagnosed celiac disease in the adult general population of Italy in 1990: Baseline reference for testing current increasing incidence?

    Bosi, Emanuele / Bazzigaluppi, Elena / Scavini, Marina / Calori, Giliola / Piemonti, Lorenzo / Lampasona, Vito

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

    2023  Volume 55, Issue 8, Page(s) 1156–1157

    MeSH term(s) Humans ; Adult ; Celiac Disease/diagnosis ; Celiac Disease/epidemiology ; Prevalence ; Incidence ; Italy/epidemiology ; Gliadin
    Chemical Substances Gliadin (9007-90-3)
    Language English
    Publishing date 2023-06-07
    Publishing country Netherlands
    Document type Letter ; Comment
    ZDB-ID 1459373-7
    ISSN 1878-3562 ; 1125-8055
    ISSN (online) 1878-3562
    ISSN 1125-8055
    DOI 10.1016/j.dld.2023.05.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: COVID-19 and islet transplantation: Different twins.

    Piemonti, Lorenzo / Landoni, Giovanni

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

    2020  Volume 20, Issue 11, Page(s) 2983–2988

    Abstract: For those who work in the field of islet transplantation, the microvascular coronavirus disease 2019 (COVID-19) lung vessels obstructive thrombo-inflammatory syndrome (recently referred to as MicroCLOTS) is familiar, as one cannot fail to recognize the ... ...

    Abstract For those who work in the field of islet transplantation, the microvascular coronavirus disease 2019 (COVID-19) lung vessels obstructive thrombo-inflammatory syndrome (recently referred to as MicroCLOTS) is familiar, as one cannot fail to recognize the presence of similarities with the instant blood mediated inflammatory reaction (IBMIR) occurring in the liver hours and days after islet infusion. Evidence in both MicroCLOTS and IBMIR suggests the involvement of the coagulation cascade and complement system activation and proinflammatory chemokines/cytokines release. Identification and targeting of pathway(s) playing a role as "master regulator(s)" in the post-islet transplant detrimental inflammatory events could be potentially useful to suggest innovative COVID-19 treatments and vice versa. Scientific organizations across the world are fighting the COVID-19 pandemic. Islet transplantation, and more generally the transplantation scientific community, could contribute by suggesting strategies for innovative approaches. At the same time, in the near future, clinical trials in COVID-19 patients will produce an enormous quantity of clinical and translational data on the control of inflammation and complement/microthrombosis activation. These data will represent a legacy to be transformed into innovation in the transplant field. It will be our contribution to change a dramatic event into advancement for the transplant field and ultimately for our patients.
    MeSH term(s) Biomarkers/metabolism ; Blood Coagulation ; COVID-19/blood ; COVID-19/epidemiology ; Comorbidity ; Complement Activation ; Cytokines/blood ; Humans ; Islets of Langerhans Transplantation/methods ; Pancreatic Diseases/epidemiology ; Pancreatic Diseases/surgery ; Pandemics ; SARS-CoV-2 ; Transplantation, Heterologous
    Chemical Substances Biomarkers ; Cytokines
    Keywords covid19
    Language English
    Publishing date 2020-06-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2060594-8
    ISSN 1600-6143 ; 1600-6135
    ISSN (online) 1600-6143
    ISSN 1600-6135
    DOI 10.1111/ajt.16001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Bioengineering the Vascularized Endocrine Pancreas: A Fine-Tuned Interplay Between Vascularization, Extracellular-Matrix-Based Scaffold Architecture, and Insulin-Producing Cells.

    Pignatelli, Cataldo / Campo, Francesco / Neroni, Alessia / Piemonti, Lorenzo / Citro, Antonio

    Transplant international : official journal of the European Society for Organ Transplantation

    2022  Volume 35, Page(s) 10555

    Abstract: Intrahepatic islet transplantation is a promising β-cell replacement strategy for the treatment of type 1 diabetes. Instant blood-mediated inflammatory reactions, acute inflammatory storm, and graft revascularization delay limit islet engraftment in the ... ...

    Abstract Intrahepatic islet transplantation is a promising β-cell replacement strategy for the treatment of type 1 diabetes. Instant blood-mediated inflammatory reactions, acute inflammatory storm, and graft revascularization delay limit islet engraftment in the peri-transplant phase, hampering the success rate of the procedure. Growing evidence has demonstrated that islet engraftment efficiency may take advantage of several bioengineering approaches aimed to recreate both vascular and endocrine compartments either
    MeSH term(s) Bioengineering ; Extracellular Matrix ; Humans ; Insulins ; Islets of Langerhans/blood supply ; Islets of Langerhans Transplantation/methods
    Chemical Substances Insulins
    Language English
    Publishing date 2022-08-25
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 639435-8
    ISSN 1432-2277 ; 0934-0874
    ISSN (online) 1432-2277
    ISSN 0934-0874
    DOI 10.3389/ti.2022.10555
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top